Covid-19 Vaccine From Novavax Begins Phase 3 Trial in U.K.
Surge in British cases offers opportunity to determine if shots works safely ahead of planned U.S. Phase 3
By Peter Loftus
Novavax Inc. NVAX 8.08% said Thursday it has started a final-stage, 10,000-person study of its experimental Covid-19 vaccine in the U.K., where a recent surge in cases could hasten an answer about whether the inoculation safely protects people from the new coronavirus.
The Gaithersburg, Md., company said the pivotal Phase 3 trial in the U.K. would track whether adults receiving its two-dose vaccine experience a lower rate of symptomatic Covid-19 compared with study subjects who get a placebo.
Novavax still plans to test its vaccine in a Phase 3 trial in the U.S. with up to 30,000 subjects, which could start in October, said Gregory Glenn, Novavax’s president of research and development.
“The U.K. trial is a different shot on goal,” Dr. Glenn said in an interview. “They look like they are going to have a big surge in disease.”
The best of the Muslim Times’ collection for war against Covid 19:
In this day and age, understanding bacteria and viruses and developing vaccines are national security issues. In my view sizable part of every country’s defense budget should be spent in these pursuits rather than making tanks and other weapons.
For the latest news about drugs and vaccines’ trials please go to: Pharmaceutical-Technology
For the latest health news from BBC, Please click here
The Muslim Times has the best collections in the war against Covid 19 as we are collecting from all the established sources
For the number of cases and epidemiology in each country go to: WorldOMeters
DAILY NEW CASES AND DEATHS IN US, CDC SITE